Pune, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Global Prothrombin Complex Concentrate Market size is projected to reach USD 1,604.9 million by 2027, exhibiting a CAGR of 10.6% during the forecast period.

PARAMUS, N.J., July 26, 2023 – Octapharma USA today announced that Balfaxar ® (prothrombin complex concentrate, human-lans; marketed in Europe and Canada as octaplex ®) has received U.S. Food and Drug ...

Pune, July 22, 2020 (GLOBE NEWSWIRE) -- The global prothrombin complex concentrate (PCC) market size is projected to reach USD 1,604.9 million by 2027, exhibiting a CAGR of 10.6% during the forecast ...

PARAMUS, N.J., April 2, 2025 /PRNewswire/ -- Octapharma USA announced the Journal of the American Medical Association (JAMA) has published results from a Phase III clinical trial, which observed ...

UAB’s Center for Injury Science (CIS) Director Jan Jansen, MBBS, Ph.D., Executive Director Shan non Stephens, EMTP, and senior scientist John Holcomb, M.D., were featured in the 2nd Annual (Trauma and ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Credit: Octapharma. Balfaxar is a human plasma-derived, purified, virus inactivated and nanofiltered non-activated prothrombin complex concentrate. Balfaxar ® (prothrombin complex concentrate, ...

CHICAGO, IL—A shelf-stable blood product may be a reasonable alternative to frozen plasma in cardiac surgery patients who experience bleeding, the FARES-II trial suggests. The four-factor prothrombin ...

TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech ...

About The Study: In this unblinded randomized clinical trial, prothrombin complex concentrate had superior hemostatic efficacy and safety advantages to frozen plasma among patients requiring ...